Arcutis Biotherapeutics
Arcutis Biotherapeutics' revenue rose 91.3% to $376 million in fiscal 2025. Its operating margin was −3.2%, up from −65.3% a year earlier. Free cash flow was −$6 million. The diluted share count rose 5.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Arcutis Biotherapeutics does
Arcutis Biotherapeutics sells prescription treatments for skin diseases. It describes itself as a commercial-stage company, meaning its products are approved and on sale, and it says it has four approved products.
Its lead product is ZORYVE, a once-daily, steroid-free medicine based on roflumilast, which blocks an enzyme called PDE4. ZORYVE cream launched in the U.S. in August 2022 for plaque psoriasis and is now approved for patients as young as 6; Arcutis has asked the FDA to extend this to children down to age 2. ZORYVE foam is approved for seborrheic dermatitis, a scaly skin condition, in people 9 and older. ZORYVE cream also launched in Canada in 2023.
Arcutis makes money by selling these products, which depend on doctors prescribing them and on insurers paying for them. It also has other product candidates in development. It has a loan agreement with operating and financial conditions it must meet.
Its biggest risks, as it describes them
- It has lost money since it began and could keep doing so.
- Its business depends on the commercial success of ZORYVE and on new products getting approved.
- Insurers and drug plans may not cover its products or may pay too little for them.
- Its loan agreement has operating and financial conditions that limit its flexibility.
- Clinical trials are slow, costly and uncertain.
Income statement
Arcutis Biotherapeutics lost money in fiscal 2025: a net loss of $16 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 387 | 410 | 272 | 228 | 221 |
| Debt incl. finance leases | 72 | 198 | 202 | 107 | 109 |
| Net debt (negative means net cash) | −315 | −212 | −70 | −121 | −112 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.2x | 0.9x | 2.3x | 0.7x | 0.6x |
| Interest coverage | — | −19.3x | −8.1x | −4.7x | −1.0x |
| Current ratio | 12.1x | 11.6x | 7.1x | 4.2x | 3.2x |
| Quick ratio | 12.1x | 11.4x | 6.8x | 4.0x | 3.0x |
Cash flow
Projections
Project Arcutis Biotherapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Arcutis Biotherapeutics says to expect
- Full year 2026: net product sales
The Company raised net product sales guidance for the full year 2026 to $535 million–$545 million from $525 million–$540 million.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Arcutis Biotherapeutics shares on the open market, and 10 insiders sold $12.2 million, $9.6 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | Masaru MatsudaSee Remarks | Sold plan | 3,674 | $25.00 | $91,850 | Form 4 |
| Sep 15, 2026 | Howard G. WelgusDirector | Sold plan | 4,730 | $24.18 | $114,371 | Form 4 |
| Sep 8, 2026 | Masaru MatsudaSee Remarks | Sold plan | 9,989 | $25.03 | $250,025 | Form 4 |
| Aug 27, 2026 | Terrie CurranDirector | Sold | 38,200 | $25.03 | $956,146 | Form 4 |
| Aug 20, 2026 | Terrie CurranDirector | Sold | 1,072 | $26.04 | $27,915 | Form 4 |
| Aug 19, 2026 | Patrick BurnettSee Remarks | Sold | 1,697 | $27.00 | $45,819 | Form 4 |
| Aug 17, 2026 | Howard G. WelgusDirector | Sold plan | 4,730 | $26.18 | $123,831 | Form 4 |
| Aug 12, 2026 | Patrick BurnettSee Remarks | Sold | 6,700 | $26.08 | $174,736 | Form 4 |
| Aug 11, 2026 | Patrick BurnettSee Remarks | Sold | 8,300 | $26.52 | $220,116 | Form 4 |
| Aug 3, 2026 | Todd WatanabeSee Remarks, Director | Sold plan | 4,375 | $26.12 | $114,275 | Form 4 |
| Aug 3, 2026 | Masaru MatsudaSee Remarks | Sold plan | 1,230 | $26.12 | $32,128 | Form 4 |
| Aug 3, 2026 | Patrick BurnettSee Remarks | Sold plan | 955 | $26.12 | $24,945 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 4 of 9 | 4 of 9 |
| Rule of 40 | 1,101.9% | 172.6% | 89.7% |
| Altman Z'' | −8.30 | −7.30 | −3.68 |
| Accruals ratio | −3.8% | −8.1% | −2.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Pass |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 4 of 9 | 4 of 9 | 4 of 9 |
Compare
Put Arcutis Biotherapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Arcutis Biotherapeutics | FY25 | 91.3% | −3.2% | −1.7% | −16.9% | — | 4 | |
| MannKind | FY25 | 22.2% | 11.1% | 3.9% | — | 3.6x | 4 | Compare |
| Ardelyx | FY25 | 22.1% | −10.1% | −10.8% | −36.1% | — | 2 | Compare |
| Innoviva | FY25 | 14.7% | 39.8% | 47.6% | 17.9% | — | 6 | Compare |
| CorMedix | FY25 | 617.0% | 48.2% | 55.4% | — | −0.9x | — | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | 0 | 0 | 4 | 60 | 196 | 376 |
| Revenue growth | — | — | — | — | — | 1,517.1% | 229.7% | 91.3% |
| Gross profit | — | — | — | 0 | 3 | 55 | 177 | 339 |
| Research and development | 18 | 36 | 115 | 146 | 182 | 111 | 76 | 77 |
| Operating income | −20 | −43 | −137 | −206 | −302 | −241 | −128 | −12 |
| Net income | −19 | −42 | −136 | −206 | −312 | −262 | −140 | −16 |
| Diluted EPS (US$) | −15.53 | −22.78 | −3.80 | −4.18 | −5.66 | −3.78 | −1.16 | −0.13 |
| Diluted shares (millions) | 1 | 2 | 36 | 49 | 55 | 69 | 121 | 127 |
| Cash flow | ||||||||
| Cash from operations | −14 | −43 | −113 | −175 | −258 | −247 | −112 | −6 |
| Capital expenditure | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Free cash flow | −14 | −43 | −113 | −176 | −258 | −247 | −112 | −6 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 1 | 8 | 24 | 33 | 39 | 42 | 40 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 39 | 101 | 284 | 387 | 410 | 272 | 228 | 221 |
| Debt incl. finance leases | — | — | 0 | 72 | 198 | 202 | 107 | 109 |
| Total assets | — | 107 | 298 | 408 | 449 | 341 | 349 | 433 |
| Total liabilities | — | 6 | 28 | 110 | 240 | 253 | 191 | 244 |
| Shareholders' equity | −24 | −65 | 271 | 298 | 210 | 89 | 158 | 190 |
| Margins and ratios | ||||||||
| Gross margin | — | — | — | — | 79.5% | 91.6% | 90.3% | 90.2% |
| Operating margin | — | — | — | — | −8,183.0% | −404.5% | −65.3% | −3.2% |
| Net margin | — | — | — | — | −8,449.8% | −439.8% | −71.2% | −4.3% |
| Free cash flow margin | — | — | — | — | −7,000.8% | −415.2% | −57.1% | −1.7% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | 1,101.9% | 172.6% | 89.7% |
| Return on capital | — | — | — | — | — | — | — | −16.9% |
| Return on equity | — | — | −132.0% | −72.6% | −122.8% | −175.8% | −113.8% | −9.3% |
| Return on assets | — | — | −67.0% | −58.4% | −72.7% | −66.3% | −40.6% | −4.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |